Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in ...
AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector ...
High-frequency ultrasound platform for preclinical imaging, supporting real-time visualization of small animal anatomy and ...
AstraZeneca's Saphnelo (anifrolumab) has been approved in the US for self-administration as a once-weekly autoinjector, the Saphnelo Pen, for the ...
Good day, and welcome to Ionis' First Quarter 2026 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the over to Wade Walke, Senior Vice ...
Zacks Investment Research on MSN
VKTX Q1 earnings miss on higher phase 3 development costs
Viking Therapeutics VKTX posted a first-quarter 2026 loss of $1.37 per share, wider than the Zacks Consensus Estimate of a ...
Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on procedural ...
Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with short ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results